Jun 14 2009
Berry flavonoids for menopausal women
(or bioflavonoids) are a class of plant secondary metabolites.
Jun 14 2009
(or bioflavonoids) are a class of plant secondary metabolites.
May 15 2009
Reprint of Are all estrogens the same?
In summary, no convincing evidence has been found that the estrogens mentioned differ qualitatively. Obviously quantitative differences are present due to differences in e.g. receptor affinity, metabolism (half life) and route of administration (transdermal/vaginal).
Apr 22 2009
The author concludes that bioidentical hormones should be the preferred method of hormone replacement therapy unless future randomized controlled trials show contrary evidence.
Apr 21 2009
Estrogen replacement and migraine.
Women with migraine with aura requiring estrogen replacement should be given the lowest effective dose necessary to control menopause symptoms, by a non-oral route.
Apr 02 2009
Exercise for vasomotor menopausal symptoms.
“No conclusions regarding the effectiveness of exercise as a treatment for vasomotor menopausal symptoms could be made due to a lack of trials.”
Apr 01 2009
Phytoestrogens for vasomotor menopausal symptoms.
“AUTHORS’ CONCLUSIONS: There is no evidence of effectiveness in the alleviation of menopausal symptoms with the use of phytoestrogen treatments.”
Mar 08 2009
Cholesterol was lower and quality of life was improved after 6 months of Tai Chi. More research will be needed to confirm this reduction in cardiovascular risk factors.
Feb 15 2009
Bioidentical hormone therapy: a panacea that lacks supportive evidence.
Most medical organizations have in essence refuted the bioidentical hormone therapy claims as unsubstantiated.
Feb 14 2009
Cortisol decreased in association with genital sexual arousal and dating women exhibited higher genital sexual arousal than single or partnered women.
Feb 13 2009
Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
In conclusion, while all types of hormone replacement therapies are
safe and effective and confer significant benefits in the long-term
when initiated in young postmenopausal women, in specific clinical
settings the choice of the transdermal route of administration of
estrogens and the use of natural progesterone might offer significant
benefits and added safety.